TCMC Trustee to receive John Vane Lecture Award
Wednesday, May 29, 2020
The William Harvey Research Institute (WHRI) at St. Bartholomews Hospital and The London School of Medicine and Dentistry St. Mary’s College has announced that Robert W. Naismith, PhD is this year’s recipient of the John Vane Lecture Award. Dr. Naismith is a founding member and former chair of the Board of Trustees at The Commonwealth Medical College (TCMC). He will deliver the WHRI’s Annual Research Review John Vane Lecture on July 3, 2020 in London, England.
“On behalf of the entire TCMC community, I congratulate Dr. Naismith on
this prestigious honor,” said Steven J. Scheinman, MD, president and
dean of TCMC. “We are fortunate to have his leadership and expertise in
advancing the mission of TCMC and medical education in the region.”
Sir John Vane was a Nobel laureate and founder of the WHRI. WHRI is a
world-leading pharmacological center with a vibrant, multidisciplinary
scientific environment devoted to therapeutic innovation in
cardiovascular, inflammatory and endocrine diseases. The William Harvey
board made the unanimous decision to invite Dr. Naismith to deliver the
John Vane Lecture in April 2013.
“Dr. Robert Naismith is an outstanding recipient of the John Vane
Lecture Award,” stated Mark Caulfield, MD, director of the William
Harvey Research Institute at Barts and The London, Queen Mary University
of London. “This award recognizes his personal success in establishing
analytic approaches for industry supporting effective therapeutic
innovation and provides living testament to his tremendous commitment to
improved healthcare worldwide.”
In addition to receiving this prestigious award, Dr. Naismith was the
recipient of the 2009 Charles R. Bost MD award from the Scranton Temple
Residency Program (The Wright Center for Graduate Medical Education).
Dr. Naismith currently serves as chairman and CEO of Roosevelt Capital
Partners, LLC, JUJAMA, Inc. and India based Mentor Insight, PVT.LTD.
Formerly he served as chairman and CEO of Life Science Analytics which
he sold to the London-based Datamonitor. Dr. Naismith co-founded
Pharmakon Research International, Inc., a preclinical contract research
organization which was sold to Princeton based DNX Corporation and
founded Biofor, Inc., a biopharmaceutical company where he served as its
president and CEO prior to its sale to Atlanta based Scherer Healthcare.
Previously he served as Chairman of the Board of the publicly-traded
companies, DermaSciences, Inc. and the Microcap Company and of the
privately-held, Emedsecurities, Inc. and NND Biomedical Sciences PVT,
LTD, India. Dr. Naismith also serves as a director of Penn Security
Bank, St. Charles Pharmaceuticals, and the Life Sciences Greenhouse of
Central PA; a trustee of the William Harvey Research Institute, London,
UK; and a member of the Kania School of Management and Panuska College
of Professional Studies and Administration Advisory Boards at The
University of Scranton as well as chairman of the International Advisory
Board of BioAsia 2010, India. Formerly he served as an adjunct professor
in the School of Medicine at Case Western Reserve University, The
Pennsylvania State University, The University of Scranton and The
Commonwealth Medical College, Dr. Naismith holds a PhD in genetics from
the Pennsylvania State University.
To learn more about WHRI, visit www.whri.qmul.ac.uk.
Media contact:
Anne Green, Director of Marketing and Public Relations
Phone: (570) 504-9687
[email protected]